Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Field Administration of Stroke Therapy-Blood Pressure Lowering (FAST-BP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01811693
Recruitment Status : Terminated (The funding period for the study has ended.)
First Posted : March 14, 2013
Results First Posted : October 29, 2020
Last Update Posted : October 29, 2020
Sponsor:
Information provided by (Responsible Party):
Jeffrey L. Saver, University of California, Los Angeles

Brief Summary:
This is an open, pilot, dose-escalation study of glyceryl trinitrate (GTN, Nitroglycerin) administered by paramedics in the field within 2 hours of symptom onset to 45 severely hypertensive stroke patients. The primary objective of the study is to evaluate the feasibility, safety, and physiologic efficacy of field-initiated glyceryl trinitrate in achieving modest reduction of blood pressure. Patients with acute stroke will be identified in the field by paramedics who have received training in basic and advanced cardiac life support, stroke recognition, and specific procedures relevant to the proposed study. Physician-investigators will obtain informed consent for each subject for study entry after cellular phone contact with paramedics. Paramedics will initiate antihypertensive treatment by applying transdermal GTN patch in the first two dose-tiers, and administering a single sublingual GTN metered spray followed by application of the transdermal system in the last dose tier. The sites involved in the study will be emergency medical services rescue ambulances and 8 receiving Stroke Center hospitals in Orange County, California, USA.

Condition or disease Intervention/treatment Phase
Intracerebral Hemorrhage Ischemic Stroke Drug: Glycerly Trinitrate Phase 2

Detailed Description:

The central aim of this phase 2a study is to identify a regimen of paramedic initiated glyceryl trinitrate antihypertensive therapy in acute stroke patients that is safe, is technically effective in modestly lowering blood pressure, and is optimal to advance to a pivotal trial. The study design is an open-label dose escalation study with three dose tiers,. It is anticipated that the trial will identify the most promising prehospital GTN regimen to advance to a pivotal, placebo-controlled, phase 3 trial.

Primary Hypothesis: Prehospital glyceryl trinitrate treatment reduces severely hypertensive blood pressure elevation by ED arrival.

The primary study endpoint to test this hypothesis will be the mean change in SBP from pre-treatment to ED arrival.

Secondary Hypotheses:

  1. Prehospital glyceryl trinitrate treatment reduces severely hypertensive blood pressure elevation at early post-arrival timepoints and increases the proportion of patients with target blood pressure at ED arrival and early post-arrival timepoints.

    The secondary study endpoints analyzed to test these hypotheses will be: 1) mean change in SBP from pre-treatment to 30 minutes after ED arrival and 60 minutes after ED arrival; and 2) the proportion of patients with SBP < 180 mm Hg at ED arrival, 30, and 60 minutes after arrival.

  2. Prehospital initiation of glyceryl trinitrate in the first 2 hours for severely hypertensive patients with stroke is feasible and safe.

Safety of GTN in the first 2 hours for severely hypertensive stroke patients will be assessed by analysis of serious adverse events, neurologic change, and mortality. We hypothesize that initiation of treatment of the patients in the field will be associated with a favorable side effect profile and without severe blood pressure lowering to les than 120 mm Hg systolic.

Successful completion of the study will demonstrate feasibility to recruit hypertensive stroke participants and initiate GTN therapy in the field by paramedics.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Field Administration of Stroke Therapy-Blood Pressure Lowering Pilot Trial
Study Start Date : April 2013
Actual Primary Completion Date : September 10, 2013
Actual Study Completion Date : December 9, 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dose Tier 1
Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal
Drug: Glycerly Trinitrate
5mg/24hour (0.2mg/hour) transdermal
Other Names:
  • Nitroglycerine
  • GTN

Experimental: Dose Tier 2
Glycerly Trinitrate (Nitroglycerine) 10mg/24hour (0.4mg/hour) transdermal
Drug: Glycerly Trinitrate
10mg/24hour (0.4mg/hour) transdermal
Other Names:
  • Nitroglycerine
  • GTN

Experimental: Dose Tier 3
Glycerly Trinitrate (GTN, Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal plus a single metered dose 0.4mg of sublingual GTN
Drug: Glycerly Trinitrate
10mg/24hour (0.4mg/hour) transdermal
Other Names:
  • Nitroglycerine
  • GTN

Drug: Glycerly Trinitrate
0.4 mg sublingual single metered spray
Other Names:
  • Nitroglycerine
  • GTN




Primary Outcome Measures :
  1. Participants With Systolic Blood Pressure Change of 8mmHg or More [ Time Frame: Baseline, 15 minutes after treatment ]
    The mean change in blood pressure was measured in the Emergency Department approximately 15 minutes after application of the treatment


Other Outcome Measures:
  1. Participants Experiencing Serious Adverse Events [ Time Frame: 90 days after enrollment ]
  2. Participants Exhibiting Neurological Deterioration as Indicated by a Two-point or Greater Worsening in the Glasgow Coma Scale [ Time Frame: Baseline, One hour after enrollment ]
    The Glasgow Coma Scale (GCS) score measures level of consciousness in eye, motor, and verbal components. At least one point is given in each category. The scale ranges from 3 to 15, with 3 indicating deep unconsciousness and 15 indicating consciousness is not impaired.

  3. Participants With Systolic Blood Pressure Less Than 120 mm/Hg [ Time Frame: 24 hours after enrollment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Suspected stroke identified with Los Angeles Prehospital Stroke Screen
  2. Age 40-80, inclusive
  3. Last known well time within 2 hours of treatment initiation
  4. Deficit present for > 15 minutes
  5. Systolic blood pressure ≥180

Exclusion Criteria:

  1. Coma
  2. Rapidly improving neurologic deficit
  3. Pre-existing neurologic, psychiatric, or advanced systemic disease that would confound the neurological or functional outcome evaluations
  4. Severe respiratory distress (O2 sat < 90% or respiratory rate < 12 or > 24)
  5. Major head trauma in the last 24 hours
  6. Recent stroke within prior 30 days
  7. Use of erectile dysfunction therapies in the previous 12 hours
  8. Use of type V phosphodiesterase inhibitors
  9. Patient unable to give informed consent and no available legally authorized representative (LAR) to provide informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01811693


Locations
Layout table for location information
United States, California
Los Alamitos Medical Center
Los Alamitos, California, United States, 90720
FAST-MAG Clinical Trial Coordinating Center
Los Angeles, California, United States, 90024
Sponsors and Collaborators
University of California, Los Angeles
Layout table for additonal information
Responsible Party: Jeffrey L. Saver, Principal Investigator, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT01811693    
Other Study ID Numbers: FBP001
First Posted: March 14, 2013    Key Record Dates
Results First Posted: October 29, 2020
Last Update Posted: October 29, 2020
Last Verified: October 2020
Keywords provided by Jeffrey L. Saver, University of California, Los Angeles:
Stroke
Intracerebral Hemorrhage
Prehospital
Antihypertensive
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebral Hemorrhage
Hemorrhage
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Intracranial Hemorrhages
Nitroglycerin
Vasodilator Agents